First results of the Phase II TITAN trial: anti-von Willebrand ... - Ablynx
First results of the Phase II TITAN trial: anti-von Willebrand ... - Ablynx
First results of the Phase II TITAN trial: anti-von Willebrand ... - Ablynx
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Immunosuppressive agents<br />
• Corticosteroids<br />
– <strong>the</strong> use <strong>of</strong> glucocorticoids is based only on clinical experience and case<br />
series<br />
(Vesely et al Blood 2003, Perotti et al Haematologica 1996, Coppo et al BJH 2006, Cataland et al BJH 2007)<br />
– in combination with PE increased complete remission rate and decreased<br />
exacerbation and relapse rates<br />
(Vesely et al Blood 2003, Coppo et al BJH 2006, Cataland et al BJH 2007, Baduini et al Ann Hematol 2010)<br />
• Rituximab<br />
– 95% had a complete clinical and laboratory response within 1-3 weeks<br />
– mild acute reactions to rituximab infusions easily managed<br />
– more serious complications were uncommon<br />
– number <strong>of</strong> PE to remission, inpatient stay and relapse rate reduced<br />
(Gutterman LA et al Blood Cells Mol Dis 2002, Galbusera M et al Blood 2005, Herbei L & Venugopal P Clin<br />
Adv Hematol Oncol 2006, Scully M et al BJH 2007, Heidel F et al TH 2007, Patino W & Sarode R J Clin Apher<br />
2007, Scully M et al BJH 2008, Bresin E et al TH 2009, Scully M et al Blood 2011)<br />
9
Change language